Related Experiment Videos
Single-dose daclizumab induction therapy in patients with liver transplantation
1Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China. yanlunan@hotmail.com
Aim:
To investigate the efficacy and safety of a single-dose daclizumab induction therapy in orthotopic liver transplantation (OLTx).
Methods:
A retrospective study was made for 54 cases of OLTx in recent three years. The daclizumab group consisted of 23 cases of OLTx who received single-dose of 2 mg/kg intravenously after postoperative 24 hours. The control group consisted of the remaining 31 patients. Additional immunosuppressors included steroids, mycomphenolate mofetil, facrolimus or microemulsion cyclosporine used in all patients. Meta-statistical analysis was made for general data, incidence of acute rejection and infection, postoperative clinical course, complications and prognosis between two groups.
Results:
Pretransplant demographies were not significantly different between two groups. In the induction group there were significantly less acute rejection episodes (5 of 23, 21.74 %) than those in the control group (12 of 31, 38.71 %), which were proved by pathologic diagnosis (P<0.05). The incidence of infection at the early stage was not significantly different between two groups.
Conclusion:
Induction therapy with single-dose of daclizumab is safe and effective and appears to be able to reduce the incidence of acute rejection.